We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
323 result(s) found, displaying 21 to 30
-
-
Prescription medicine registrationActive ingredients: datopotamab deruxtecan.
-
-
-
Prescription medicine registrationActive ingredients: dapagliflozin propanediol monohydrate.
-
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
-
Australian public assessment report (AusPar)Truqap (capivasertib), in combination with fulvestrant, was approved for the treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer following recurrence or progression on or after an endocrine-based regimen.
-